TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Alvotech ( (ALVO) ).
On November 24, 2025, Alvotech announced that its biosimilar AVT03, equivalent to Prolia and Xgeva (denosumab), received approval for marketing in the European Economic Area. This approval is a significant milestone for Alvotech, enhancing its biosimilar portfolio and reinforcing its position as a key partner in European healthcare systems. The introduction of AVT03 is expected to broaden access to essential osteoporosis and oncology treatments, supporting sustainable healthcare budgets by offering cost-effective alternatives. The European denosumab market, valued at approximately $1.2 billion, will benefit from Alvotech’s partnerships with STADA and Dr. Reddy’s, who will commercialize AVT03 under different brand names in Europe.
The most recent analyst rating on (ALVO) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
Spark’s Take on ALVO Stock
According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.
Alvotech’s overall stock score is primarily impacted by its financial performance and technical analysis. The company’s high leverage and negative equity pose significant financial risks, while bearish technical indicators suggest continued downward pressure on the stock. The moderate valuation provides some support, but the lack of a dividend yield is a drawback. Despite strong revenue growth and strategic investments, regulatory and operational challenges weigh heavily on the outlook.
To see Spark’s full report on ALVO stock, click here.
More about Alvotech
Alvotech is a global biotech company focused on the development and manufacture of biosimilar medicines. Founded by Robert Wessman, the company aims to be a leader in the biosimilar space by providing high-quality, cost-effective products. Alvotech has a diverse pipeline targeting autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer, and has established strategic commercial partnerships worldwide, including in the United States, Europe, Japan, China, and other regions.
Average Trading Volume: 500,173
Technical Sentiment Signal: Sell
Current Market Cap: $1.55B
See more insights into ALVO stock on TipRanks’ Stock Analysis page.